NovoCure Ltd

NVCR

Explore Our Financial Data > Companies > NovoCure Ltd

Identification

Click on a field for details on how to access that data via Web API, Excel, or CSV Download.

Ticker	NVCR
CIK	0001645113
SIC	3841
Sector	Manufacturing
Industry Category	Medical Equipment
Industry Group	Surgical, Medical, And Dental Instruments And Supplies

Contact

Address	NO. 4 THE FORUM, GRENVILLE STREET, ST. HELIER, Y9, JE2 4UF
Website	novocure.com
Phone	44 (0)15 3475 6700
CEO	Asaf Danziger
Employees	1,320

Access This Data

Our team will help you customize a package that meets the needs of your business.

Request a Consultation

Standardized Financials

docs

Intrinio provides professional-grade historical financial data. This data is standardized, cleansed and verified to ensure the highest quality data sourced directly from the XBRL financial statements. The primary purpose of standardized financials are to facilitate comparability across a single company’s fundamentals and across all companies fundamentals.

For example, it is possible to compare total revenues between two companies as of a certain point in time, or within a single company across multiple time periods. This is not possible using the as reported financial statements because of the inherent complexity of reporting standards.

Below is a preview of several data points from each financial statement, as well as a sample of our many calculated metrics:

Income Statement

Revenue	$630.16 million
Pre-Tax Income	$-142.06 million
Net Income	$-170.95 million
Net Income to Common	$-170.95 million
EPS	$-1.56

View All

Balance Sheet

Cash	$149.62 million
Assets	$1.25 billion
Liabilities	$896.43 million
Common Equity	$349.44 million
Liabilities & Equity	$1.25 billion

View All

Cash Flow Statement

Net Income	$-170.95 million
Cash From Operating Activities	$-44.68 million
Cash From Investing Activities	$17.50 million
Cash From Financing Activities	$10.42 million
Change in Cash	$-16.31 million

View All

Calculations

NOPAT	$-120.95 million
EBITDA	$-186.97 million
Price to Earnings	N/A
Price to Book	$3.74
ROE	-48.07%

View All

Latest News

docs

Intrinio provides up-to-date news articles on every US company from various sources. Here are several examples:

NVCR Stock Slips Despite PMA Application to Treat Pancreatic Cancer

NovoCure submits a PMA to the FDA for TTFields therapy in pancreatic cancer, aiming to expand its oncology reach.

Article Link

Novocure Submits Premarket Approval Application to FDA for Tumor Treating Fields Therapy in Locally Advanced Pancreatic Cancer

BAAR, Switzerland, August 20, 2025--Novocure (NASDAQ: NVCR) today announced it submitted a premarket approval (PMA) application to the U.S. Food and Drug Administration (FDA) for Tumor Treating Fields (TTFields) therapy for the treatment of locally advanced pancreatic cancer.

Article Link

Leerink Partners Reiterates a Buy Rating on NovoCure Limited (NVCR)

NovoCure Limited (NASDAQ:NVCR) is one of the best medical device stocks to buy according to analysts. Leerink Partners analyst Jonathan Chang reiterated a Buy rating on NovoCure Limited (NASDAQ:NVCR) on July 24, setting a price target of $33.00. The analyst told investors that NovoCure Limited (NASDAQ:NVCR) reported solid results for fiscal Q2 2025, exceeding revenue expectations […]

Article Link

NovoCure Second Quarter 2025 Earnings: Beats Expectations

NovoCure ( NASDAQ:NVCR ) Second Quarter 2025 Results Key Financial Results Revenue: US$158.8m (up 5.6% from 2Q 2024...

Article Link

NovoCure: Q2 Earnings Snapshot

ST. HELIER, Jersey (AP) — NovoCure Ltd. (NVCR) on Thursday reported a loss of $40.1 million in its second quarter. On a per-share basis, the St. Helier, Jersey-based company said it had a loss of 36 cents.

Article Link